Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
| ▸ | HRH2 | P25021 | 2/20 | 0.37 |
| ▸ | HRH1 | P35367 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24764732 | 1.00 | MEN1 (0.41) | MEN1KMT2APOLBSMN1; SMN2KDM4E | |
| SCHEMBL22128496 | 1.00 | MEN1 (0.41) | MEN1KMT2APOLBSMN1; SMN2KDM4E | |
| SCHEMBL7304959 | 0.96 | POLB (0.42) | MEN1KMT2APOLBSMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL7311470 | 0.95 | POLB (0.41) | MEN1KMT2APOLBSMN1; SMN2KDM4E | |
| Trifluoroacetic Acid SCHEMBL31732071 | 0.86 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL24533526 | 0.83 | KDM4E (0.40) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL23987984 | 0.82 | CXCR4 (0.52) | MEN1KMT2APOLBSMN1; SMN2KDM4E | |
| SCHEMBL5322116 | 0.79 | HRH3 (0.41) | SMN1; SMN2KDM4EALDH1A1HRH3LTA4H | |
| SCHEMBL23100650 | 0.79 | KDM4E (0.36) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL22788623 | 0.79 | KDM4E (0.36) | MEN1KMT2AKDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024010810-A2 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| WO-2022133281-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2018128826-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | MEN1 3001/4885KMT2A 4310/4885POLB 1639/4885 |
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | MEN1 3001/4885KMT2A 4310/4885POLB 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.